Amneal Pharmaceuticals
As of the edition of 20 October 2026, Amneal Pharmaceuticals runs 20 drugs, 14 of them marketed; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Active | 1 |
| Went quiet | 4 |
| Status not established | 1 |
| Total | 20 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Epinephrine | none listed | 23 |
| Sodium bicarbonate | none listed | 0 |
| Albendazole | none listed | 0 |
| Baclofen | none listed | 1 |
| Tigecycline | none listed | 0 |
| Opicapone | Ends 2032 (patent) | 2 |
| Dextroamphetamine | none listed | 3 |
| Pyridostigmine | none listed | 0 |
| Zolmitriptan | none listed | 2 |
| Dihydroergotamine | none listed | 1 |
| Reserpine | none listed | 0 |
| Cortisone acetate | none listed | 2 |
| Rauwolfia serpentina | none listed | 1 |
| Meprobamate | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Amneal Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 13 trials led
- Bones, joints and muscles: 1 trials led
- Immune system: 1 trials led